General Medicine raises $120M to sell drugs, lab tests and visits with upfront prices
Andreessen Horowitz led the Series B, which brings the San Francisco company's funding to $152 million. Former Matrix general partner TJ Parker is now CEO, and Eli Lilly is among the investors.

- Amount
- $120M
- Type
- Series B
- Company
- General Medicine
- Lead investor
- Andreessen Horowitz
- Sector
- Digital Health
- Announced
- Oct. 6, 2026
General Medicine sells health care the way online retailers sell everything else: a searchable catalog, a posted price and a checkout. The San Francisco company said Oct. 6 that Andreessen Horowitz led a $120 million Series B round meant to stock more of the shelves.
Matrix, VXI Capital, Eli Lilly and Company, Mercy Health through Granger Management, and BoxGroup also invested, the company said. Vineeta Agarwala, a general partner at Andreessen Horowitz, led the deal. General Medicine has now raised $152 million in all and did not disclose a valuation.
Why it matters: The money backs a model in which consumers buy care directly, with or without insurance, and see the price before they commit. General Medicine sells medications, and Eli Lilly and Company invested in this round; the company said neither its investors nor its commercial partners determine which products appear to shoppers or what its clinicians recommend.
How the store works
General Medicine says its catalog holds over 2,900 items, from prescriptions and lab work to virtual visits, specialist e-consults and a limited set of in-person appointments and procedures. Shoppers can buy directly, ask a licensed clinician for a recommendation, usually the same day according to the company, or use an AI chat to talk through symptoms and options.
The company said its catalog reconciles the different names that patients, clinicians, insurers, labs and health systems use for the same service, which it said is what lets customers compare prices. When a purchase needs clinical review, a clinician decides whether it is appropriate, according to the release.
Since its May 2025 nationwide launch, the company says, its customer count has reached the hundreds of thousands, and it averages a Net Promoter Score of 80. It said 83% of customers report it helped them deal with a health problem they had been postponing, and that about one in three had waited over six months to seek care.
"Everyone's building a healthcare AI agent that can tell you what you might need. What's missing is the infrastructure that lets you actually get it," TJ Parker, the chief executive, said in the announcement. The company said it expects AI agents to be able to buy care for people through the same system customers use today.
Elliot Cohen, the president, cast price visibility as pressure on incumbents. "When a customer can actually see their options and the price, the rest of the system has to compete," Cohen said, adding that this holds for insurers, health systems and drugmakers alike.
A new chief executive
The financing came with a change at the top. Parker became chief executive full time in October after working as a Matrix general partner, a role in which he led the firm's early investments in General Medicine. He has sat on the board since the company's founding and still holds a venture partner title at Matrix.
Ashwin Muralidharan, the founding CEO, moved to chief product officer and still oversees product, engineering, design, clinical work and much of daily operations, the company said. The three co-founders started General Medicine in fall 2023. It has its headquarters in San Francisco and an office presence in Boston.
General Medicine said it will use the new money to add more categories of care to the store. It did not say which categories come next or when they will launch.



